KRAS and colorectal carcinoma: The results of our cell viability assay indicate that while the KRAS WT CRC cells show 7.7% (p < 0.005) and 16.5% (p < 0.01) decreases in cell viability, after 60 h of treatment with 1 μM & 10 μM concentrations of PRMT5 inhibitor, respectively, the KRAS mutant CRC cells show more substantial 18.4% (p < 0.005) and 32.6% (p < 0.005) decreases in cell viability, respectively.